Related references
Note: Only part of the references are listed.Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase
Nikolaj H. T. Petersen et al.
CANCER CELL (2013)
Combating apoptosis and multidrug resistant cancers by targeting lysosomes
Line Groth-Pedersen et al.
CANCER LETTERS (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
Pankaj Gupta et al.
BLOOD (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
Lapo Alinari et al.
BLOOD (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways
Rhona Stein et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
Edmund A. Rossi et al.
CANCER RESEARCH (2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells
A. Puissant et al.
LEUKEMIA (2010)
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Ezogelin Oflazoglu et al.
MABS (2010)
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
Bohua Li et al.
BLOOD (2009)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
Ali R. Jazirehi et al.
CANCER RESEARCH (2007)
Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Rhona Stein et al.
BLOOD (2006)
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
C Bezombes et al.
BLOOD (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
HLA class II antibodies in the treatment of hematologic malignancies
M Dechant et al.
SEMINARS IN ONCOLOGY (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Improving the efficacy of antibody-based cancer therapies
P Carter
NATURE REVIEWS CANCER (2001)
Bispecific human IgG by design
P Carter
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Share Paper
